Neervannan Seshadri 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 11, 2024
Insider Transaction Report
Form 4
Neervannan Seshadri
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2024-03-07+47,500→ 47,500 totalExercise: $35.50Exp: 2034-03-06→ Common Stock (47,500 underlying) - Award
Restricted Stock Units
2024-03-07+32,079→ 32,079 total→ Common Stock (32,079 underlying)
Footnotes (3)
- [F1]25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F3]25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service.